Technology | Image Guided Radiation Therapy (IGRT) | April 24, 2019

Accuray Launches Synchrony Motion Tracking and Correction Technology for Radixact System

Intrafraction motion synchronization allows real-time tracking visualization and correction for tumor motion during treatment

Accuray Launches Synchrony Motion Tracking and Correction Technology for Radixact System

April 24, 2019 — Accuray announced the launch of its Synchrony motion tracking and correction technology to be used with the Radixact System for radiation therapy. This new feature adds intrafraction motion synchronization capabilities to the Radixact System, enabling real-time tracking, visualization and correction for tumor motion during treatment, with the goal of improving dose accuracy and treatment times compared to conventional radiation therapy systems. The Radixact System with Synchrony will be unveiled at the European Society for Radiotherapy & Oncology (ESTRO) meeting, April 26-30 in Milan, Italy.

Originally developed to expand on the CyberKnife System's automatic motion tracking and correction capabilities, Synchrony uses continual image guidance to automatically adjust the movement of the beam in synchronization with the movement of the target volume. The technology is designed to correct for tumors that move as a result of bodily processes, including respiration and digestion, as well as patient movement, and has the capability to perform fiducial-free tracking for lung indications.

The Radixact System is equipped with a built-in computed tomography (CT) scanner that performs daily imaging before each treatment session. This provides clinicians with information on the shape and position of the tumor, and makes it possible for them to identify and correct for any variations in patient positioning. Clinicians are then able to use Synchrony to automatically synchronize radiation treatment delivery to the moving tumor's location throughout the treatment session. This functionality is designed to provide highly precise radiation dose delivery to tumors that move, such as lung and prostate, and smaller treatment margins around the tumor, minimizing the amount of healthy tissue exposed to high-dose radiation.

Accuray expects to begin shipping the Synchrony technology commercially by the end of calendar year 2019.

Jennifer Smilowitz, Ph.D., clinical professor University of Wisconsin School of Medicine and Public Health, and Fellow of the American Association of Physicists in Medicine (AAPM), has been involved in the development of the Radixact System from its start. She commented, "The introduction of Synchrony for this system will enable clinicians to more easily, and efficiently, deliver precise radiation treatments to tumors that move using image-guided, intensity-modulated radiation therapy (IG-IMRT) with target tracking. In my opinion, this has the potential to expand the way the Radixact System is used, as well as the types of patients who are treated with it."

For more information: www.accuray.com

Related Content

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
January 13, 2021 — The ...
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
January 11, 2021 — A study
Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement solutions, announced that it has acquired Sun Nuclear Corporation. Sun Nuclear is the global leader in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world.
News | Quality Assurance (QA) | January 08, 2021
January 8, 2021 — Mirion Technologies, Inc., a global provider of
RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

Image courtesy of Siemens Healthineers

News | Linear Accelerators | January 04, 2021
January 4, 2021 — RAD Technology Medical Systems (RAD) ann
RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.
News | Brachytherapy Systems | December 29, 2020
December 29, 2020 — RaySearch Laboratories AB has launched the latest release of its widely adopted treatment plannin
According to recent studies, an increase in the COVID-19 positivity rate correlates to an increase in mortality from non-coronavirus-related diseases. This includes breast cancer, and researchers believe fear of contracting the virus compels patients to stay home instead of completing their post-lumpectomy radiotherapy regimens.

Image courtesy of Zeiss

News | Radiation Therapy | December 21, 2020
December 21, 2020 — According to recent studies, an increase in the...
Older patients with hormone receptor-positive breast cancer who did not receive radiation therapy after breast-conserving surgery had higher rates of local recurrence but similar 10-year survival rates when compared to patients who received postoperative radiation therapy, according to updated 10-year data from the PRIME II study, presented at the 2020 San Antonio Breast Cancer Symposium

Getty Images

News | Radiation Therapy | December 15, 2020
December 15, 2020 — Older patients with hormone receptor-positive breast cancer who did not receive radiation therapy